Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Govt Health Promotion Taskforce Seeks 152.8 Billion Yen for AMED
September 1, 2016
- “Untreated” Erased from Viekirax’s Add’l Indication: Sept. 9 Panel Meeting
August 31, 2016
- Lilly Drops Listing of Taltz amid Pricing Fuss, Wants to Deliver Drug without Restrictions
August 31, 2016
- MHLW Panel to Discuss Keytruda on Sept. 9, Listing Expected as Early as November
August 30, 2016
- MHLW Unveils FY2017 Budget Request, 105.8 Bil. Yen Sought for Healthcare Innovation
August 29, 2016
- MHLW Requests Extension of R&D Tax Credit for “High-Level Investment”
August 29, 2016
- MHLW OKs RCC Indication for Opdivo, Approval Changes to Other Drugs
August 29, 2016
- AZ’s Ticagrelor, BI’s Triple Combo to Take Another Stab to Clear MHLW Committee
August 26, 2016
- MHLW Advisory Committee to Review Reversal Agent for Prazaxa on Sept. 7
August 26, 2016
- MHLW Grants Orphan Status to Crizotinib, 3 Other Drugs
August 26, 2016
- Innovative Drugs Are Not “Villain,” Kamoya Laments
August 25, 2016
- Chuikyo Subcommittee Effectively Kicks Off Debates on FY2018 Reform, with Focus on Pricy Meds
August 25, 2016
- Discussions on Opdivo’s Special Pricing Measure Get Underway at Chuikyo Subcommittee
August 25, 2016
- After Taltz Given High Price, MHLW to Push Use of Other Psoriasis Drugs; Revision to Foreign Price Adjustment Eyed
August 25, 2016
- MHLW to Set Up Dedicated Office for Antimicrobial Resistance: FY2017 Budget
August 24, 2016
- MHLW to Seek 2 Billion Yen to Foster Healthcare Startups in FY2017
August 24, 2016
- Chuikyo OKs Praluent, 8 Other APIs for Listing on Aug. 31
August 24, 2016
- Basic Policies for JP 18th Edition Now Up for Public Comments
August 23, 2016
- Japan to Target 95-100% SVR for Hep C, Compensated Cirrhosis in Revised 10-Year Strategy
August 23, 2016
- MHLW to Seek Funding to Promote and Support Healthcare Startups in FY2017 Budget Request
August 23, 2016
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…